ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lurasidone

Also written as “Lurasidone”, “Lurasidone HCl” and “SM-13496”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Depression · Urinary Tract Infections, led by 4 companies.

Drug pageLurasidone: every studyAll 66 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 7, 202152 company-led studies, 2 open or runningNext primary completion: Oct 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sumitomo Pharma480 open or runningphase 4since Aug 7, 2021Aug 16, 2002none ahead
Bukwang Pharmaceuticalits history only21 open or runningphase 3since Mar 8, 2018Mar 8, 2018Oct 2027phase 3 · NCT07781293
NeuroRxits history only11 open or runningphase 2since Nov 7, 2023Nov 7, 2023none ahead
Standard Chem. & Pharm.its history only10 open or runningphase 4since Dec 20, 2017Dec 20, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sumitomo Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 28 studies since Aug 16, 2002.

  1. Dec 1, 2011Phase 3 study in SchizophreniaNCT01485640 · 162 enrolled · Canada, Colombia, Czech Republic and more
  2. Mar 27, 20122 phase 3 studiesNCT01566162, NCT01575561
  3. May 23, 2012Phase 1 study in SchizophreniaNCT01620060 · 105 enrolled · United States
  4. Jun 6, 20122 phase 3 studies in SchizophreniaNCT01614912, NCT01614899
  5. Mar 22, 2013Phase 3 study in SchizophreniaNCT01821378 · 412 enrolled · United States, Colombia, Romania and more
  6. Jul 22, 20133 phase 3 studiesNCT01911442, NCT01911429, NCT01914393
  7. Nov 4, 20132 phase 3 studiesNCT01986114, NCT01986101
  8. Dec 2, 2013Phase 3 study in SchizophreniaNCT02002832 · 388 enrolled · China
  9. Jan 23, 2014Phase 3 study in Bipolar DisorderNCT02046369 · 350 enrolled · United States, Bulgaria, Colombia and more
  10. Feb 11, 20142 phase 1 studies in SchizophreniaNCT02174523, NCT02174510
  11. Aug 7, 2018Phase 1 study in SchizophreniaNCT03627195 · 40 enrolled · United States
  12. Apr 16, 2020Phase 3 study in Bipolar I DepressionNCT04383691 · 124 enrolled · China
  13. Aug 7, 2021Phase 4 study in SchizophreniaNCT05011669 · 200 enrolled · China
  14. Dec 5, 2021Phase 4 study in SchizophreniaNCT05213143 · 13 enrolled · China

TargetBeta

DRD2 →HTR2A →read by rule
“Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
iloperidoneruleVanda Pharmaceuticalsphase 415
lumateperoneruleJohnson & Johnsonphase 325

Studies

All 48 Sumitomo Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05213143Schizophrenia · China4TerminatedNov 18, 202213
NCT05011669Schizophrenia · China4CompletedApr 16, 2023200
NCT04383691Bipolar I Depression · China3TerminatedDec 23, 2022124
NCT03627195Schizophrenia · United States1CompletedMar 29, 201940
NCT02174523Schizophrenia · China1CompletedApr 201414
NCT02174510Schizophrenia · China1CompletedApr 201437
NCT02046369Bipolar Disorder · United States, Bulgaria, Colombia and more3CompletedOct 2016350
NCT02002832Schizophrenia · China3CompletedApr 2015388
NCT01986114Bipolar I Disorder · Japan, Lithuania, Malaysia and more3CompletedFeb 8, 2018495
NCT01986101Bipolar Disorder · Japan, Lithuania, Malaysia and more3CompletedFeb 1, 2017525
NCT01914393Schizophrenia · United States, Bulgaria, Colombia and more3CompletedOct 17, 2018702
NCT01911442Autistic Disorder · United States3CompletedNov 2014150
NCT01911429Schizophrenia · United States, Belgium, Bulgaria and more3CompletedDec 2015327
NCT01821378Schizophrenia · United States, Colombia, Romania and more3CompletedJun 2014412
NCT01614912Schizophrenia · Japan, Korea, Republic of, Malaysia and more3CompletedMay 2015284
NCT01614899Schizophrenia · Japan, Korea, Republic of, Malaysia and more3CompletedNov 17, 2014457
NCT01620060Schizophrenia · United States1CompletedMay 2013105
NCT01575561Bipolar Disorder · United States, Argentina, Bulgaria and more3CompletedJul 2015377
NCT01566162Schizophrenia · United States, France, Italy and more3CompletedNov 2013191
NCT01485640Schizophrenia · Canada, Colombia, Czech Republic and more3CompletedFeb 2014162
NCT01435928Schizophrenia · United States, France, Italy and more3CompletedAug 2013676
NCT01423253Depressive Disorder, Major · United States3CompletedOct 201348
NCT01423240Depressive Disorder, Major · United States3WithdrawnDec 20120
NCT01421134Depression · United States, Russian Federation, Serbia and more3CompletedOct 2014211
NCT01358357Bipolar I Disorder · United States, Argentina, Australia and more3CompletedApr 2015965
NCT01284517Bipolar Disorder · United States, Canada, Colombia and more3CompletedAug 2012356
NCT01143090Schizophrenia · United States3CompletedNov 2011149
NCT01143077Schizophrenia · United States3CompletedMay 2011244
NCT01082289Schizophrenia · United States1CompletedOct 200824
NCT01082276Male, Healthy Normal Subjects · United States1CompletedAug 200820
NCT01082263Schizophrenia Patients · United States1CompletedNov 200824
NCT01082250Schizophrenia · United States1CompletedSep 200852
NCT01082146Pharmacokinetics · United States1CompletedAug 20086
NCT01074632Schizophrenia · United States1CompletedSep 200926
NCT01074073Schizophrenia · United States1CompletedOct 200824
NCT00868959Bipolar Disorder · United States, Canada, Colombia and more3CompletedFeb 2013817
NCT00868699Bipolar Disorder · United States, Czech Republic, France and more3CompletedFeb 2012505
NCT00868452Bipolar Disorder · United States, Czech Republic, France and more3CompletedDec 2011348
NCT00790192Schizophrenia · United States, India, Romania and more3CompletedJul 2010488
NCT00711269Schizophrenia · Japan, Korea, Republic of, Taiwan3CompletedApr 27, 2010460
NCT00641745Schizophrenia · United States, Argentina, Brazil and more3CompletedJul 2010629
NCT00615433Schizophrenia · United States, Colombia, India and more3CompletedDec 2009478
NCT00549718Schizophrenia · United States, France, India and more3CompletedOct 2010489
NCT00549666Pharmacokinetics · United States1CompletedDec 200723
NCT00088634Schizophrenia · United States2CompletedDec 2004180
NCT00088621Schizophrenia · United States2CompletedOct 200561
NCT00044044Schizophrenia · United States2CompletedMay 2003356
NCT00044005Schizophrenia · United States2CompletedNov 200398

How it is read

Names in the registry

  • “Lurasidone”, 22 entries
  • “Lurasidone HCl”, 10 entries
  • “SM-13496”, 4 entries
  • “Lurasidone 40 mg”, 3 entries
  • “lurasidone”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.